Reinhard Zeidler

List of Publications by Year
in descending order

54	3,091	136950 32	161849 54
papers	citations	h-index	g-index

59	59	59	5026
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	First studies on tumor associated carbonic anhydrases IX and XII monoclonal antibodies conjugated to small molecule inhibitors. Journal of Enzyme Inhibition and Medicinal Chemistry, 2022, 37, 592-596.	5.2	14
2	Uncovering the molecular identity of cardiosphere-derived cells (CDCs) by single-cell RNA sequencing. Basic Research in Cardiology, 2022, 117, 11.	5.9	7
3	A Novel Anti-CD73 Antibody That Selectively Inhibits Membrane CD73 Shows Antitumor Activity and Induces Tumor Immune Escape. Biomedicines, 2022, 10, 825.	3.2	4
4	Quantitation of SARS-CoV-2 neutralizing antibodies with a virus-free, authentic test. , 2022, 1, .		5
5	Carbonic Anhydrase XII is a Clinically Significant, Molecular Tumor-Subtype Specific Therapeutic Target in Glioma with the Potential to Combat Invasion of Brain Tumor Cells. OncoTargets and Therapy, 2021, Volume 14, 1707-1718.	2.0	12
6	MicroRNAs are minor constituents of extracellular vesicles that are rarely delivered to target cells. PLoS Genetics, 2021, 17, e1009951.	3.5	125
7	CAR-T Cells Targeting Epstein-Barr Virus gp350 Validated in a Humanized Mouse Model of EBV Infection and Lymphoproliferative Disease. Molecular Therapy - Oncolytics, 2020, 18, 504-524.	4.4	38
8	Differential effects of Belatacept on virus-specific memory versus de novo allo-specific T cell responses of kidney transplant recipients and healthy donors. Transplant Immunology, 2020, 61, 101291.	1.2	5
9	Biochemical and Structural Insights into Carbonic Anhydrase XII/Fab6A10 Complex. Journal of Molecular Biology, 2019, 431, 4910-4921.	4.2	23
10	Intracavitary radioimmunotherapy of high-grade gliomas: present status and future developments. Acta Neurochirurgica, 2019, 161, 1109-1124.	1.7	10
11	Engineering extracellular vesicles as novel treatment options: exploiting herpesviral immunity in CLL. Journal of Extracellular Vesicles, 2019, 8, 1573051.	12.2	11
12	Deep Learning Reveals Cancer Metastasis and Therapeutic Antibody Targeting in the Entire Body. Cell, 2019, 179, 1661-1676.e19.	28.9	142
13	Spatiotemporally Skewed Activation of Programmed Cell Death Receptor 1â€“Positive TâCells after Epstein-Barr Virus Infection and Tumor Development in Long-Term Fully Humanized Mice. American Journal of Pathology, 2019, 189, 521-539.	3.8	13
14	Fully Automated Production and Characterization of ⁶⁴Cu and Proofâ€ofâ€Principle Smallâ€Animal PET Imaging Using ⁶⁴Cuâ€Labelled CA XII Targeting 6A10 Fab. ChemMedChem, 2018, 13, 1230-1237.	3.2	12
15	Tumorâ€derived extracellular vesicles activate primary monocytes. Cancer Medicine, 2018, 7, 2013-2020.	2.8	18
16	An inhibitory antibody targeting carbonic anhydrase XII abrogates chemoresistance and significantly reduces lung metastases in an orthotopic breast cancer model in vivo. International Journal of Cancer, 2018, 143, 2065-2075.	5.1	42
17	EVpedia: a community web portal for extracellular vesicles research. Bioinformatics, 2015, 31, 933-939.	4.1	317
18	Latent Membrane Protein LMP2A Impairs Recognition of EBV-Infected Cells by CD8+ T Cells. PLoS Pathogens, 2015, 11, e1004906.	4.7	45

#	Article	IF	Citations
19	Esterase activity of carbonic anhydrases serves as surrogate for selecting antibodies blocking hydratase activity. Journal of Enzyme Inhibition and Medicinal Chemistry, 2015, 30, 955-960.	5.2	32
20	The role of tumour FoxP3 as prognostic marker in different subtypes of head and neck cancer. European Journal of Cancer, 2014, 50, 1291-1300.	2.8	36
21	Antitumor Efficacy of a Monoclonal Antibody That Inhibits the Activity of Cancer-Associated Carbonic Anhydrase XII. Cancer Research, 2013, 73, 6494-6503.	0.9	54
22	HIV Nef, Paxillin, and Pak1/2 Regulate Activation and Secretion of TACE/ADAM10 Proteases. Molecular Cell, 2013, 49, 668-679.	9.7	83
23	Neutrophils Activate Tumoral CORTACTIN to Enhance Progression of Orohypopharynx Carcinoma. Frontiers in Immunology, 2013, 4, 33.	4.8	32
24	AHNAK and Inflammatory Markers Predict Poor Survival in Laryngeal Carcinoma. PLoS ONE, 2013, 8, e56420.	2.5	57
25	The EBV Immunoevasins vIL-10 and BNLF2a Protect Newly Infected B Cells from Immune Recognition and Elimination. PLoS Pathogens, 2012, 8, e1002704.	4.7	139
26	Murine gammaherpesvirus 68 glycoprotein 150 does not contribute to latency amplification in vivo. Virology Journal, 2012, 9, 107.	3.4	8
27	RNAs in Epsteinâ€“Barr virions control early steps of infection. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, E1396-404.	7.1	73
28	Tumour exosomes inhibit binding of tumour-reactive antibodies to tumour cells and reduce ADCC. Cancer Immunology, Immunotherapy, 2011, 60, 639-648.	4.2	130
29	Generation and characterization of the first inhibitory antibody targeting tumour-associated carbonic anhydrase XII. Cancer Immunology, Immunotherapy, 2011, 60, 649-658.	4.2	79
30	A Virus-Like Particle-Based Epstein-Barr Virus Vaccine. Journal of Virology, 2011, 85, 13105-13113.	3.4	83
31	EBV-gp350 Confers B-Cell Tropism to Tailored Exosomes and Is a Neo-Antigen in Normal and Malignant B Cellsâ€"A New Option for the Treatment of B-CLL. PLoS ONE, 2011, 6, e25294.	2.5	65
32	Tumorâ€derived microvesicles in sera of patients with head and neck cancer and their role in tumor progression. Head and Neck, 2009, 31, 371-380.	2.0	89
33	Conditional Immortalization of Human B Cells by CD40 Ligation. PLoS ONE, 2008, 3, e1464.	2.5	84
34	Activated B Cells Mediate Efficient Expansion of Rare Antigen-Specific T Cells. Human Immunology, 2007, 68, 75-85.	2.4	16
35	Expansion of Human T Regulatory Type 1 Cells in the Microenvironment of Cyclooxygenase 2 Overexpressing Head and Neck Squamous Cell Carcinoma. Cancer Research, 2007, 67, 8865-8873.	0.9	136
36	Expansion and characteristics of human T regulatory type 1 cells in co-cultures simulating tumor microenvironment. Cancer Immunology, Immunotherapy, 2007, 56, 1429-1442.	4.2	82

#	Article	IF	Citations
37	Immune restoration in head and neck cancer patients after in vivo COX-2 inhibition. Cancer Immunology, Immunotherapy, 2007, 56, 1645-1652.	4.2	25
38	Nicotine and apoptosis. Apoptosis: an International Journal on Programmed Cell Death, 2007, 12, 1927-1943.	4.9	92
39	Carcinoma-associated eIF3i overexpression facilitates mTOR-dependent growth transformation. Molecular Carcinogenesis, 2006, 45, 957-967.	2.7	48
40	Selection of CMV-specific CD8+ and CD4+ Tâ€„cells by mini-EBV-transformed Bâ€„cell lines. European Journal of Immunology, 2005, 35, 2110-2121.	2.9	25
41	Identification of Epstein-Barr Virus (EBV) Nuclear Antigen 2 (EBNA2) Target Proteins by Proteome Analysis: Activation of EBNA2 in Conditionally Immortalized B Cells Reflects Early Events after Infection of Primary B Cells by EBV. Journal of Virology, 2004, 78, 3941-3952.	3.4	49
42	Allogenic antibody-mediated identification of head and neck cancer antigens. Biochemical and Biophysical Research Communications, 2004, 323, 156-162.	2.1	64
43	New Target Genes for Tumor-derived Soluble Factors in Primary Monocytes. Cancer Genomics and Proteomics, 2004, 1, 167-176.	2.0	1
44	Tumor-specific glycosylation of the carcinoma-associated epithelial cell adhesion molecule EpCAM in head and neck carcinomas. Cancer Letters, 2003, 193, 25-32.	7.2	78
45	Impaired monocyte function in cancer patients: restoration with a cyclooxygenaseâ€2 inhibitor. FASEB Journal, 2003, 17, 286-288.	0.5	43
46	B cells immortalized by a miniâ€“Epstein-Barr virus encoding a foreign antigen efficiently reactivate specific cytotoxic T cells. Blood, 2002, 100, 1755-1764.	1.4	66
47	B cells immortalized by a mini-Epstein-Barr virus encoding a foreign antigen efficiently reactivate specific cytotoxic T cells. Blood, 2002, 100, 1755-64.	1.4	31
48	Tumor necrosis factor ? negatively regulates the expression of the carcinoma-associated antigen epithelial cell adhesion molecule. Cancer, 2001, 92, 620-628.	4.1	36
49	The PKC targeting protein RACK1 interacts with the Epstein-Barr virus activator protein BZLF1. FEBS Journal, 2000, 267, 3891-3901.	0.2	47
50	Tumor cellâ€derived prostaglandin E2 inhibits monocyte function by interfering with CCR5 and Macâ€1. FASEB Journal, 2000, 14, 661-668.	0.5	48
51	Gene Therapy - Phase I Trial for Primary Untreated Head and Neck Squamous Cell Cancer (HNSCC) UICC Stage II-IV with a Single Intratumoral Injection of hIL-2 Plasmids Formulated in DOTMA/Chol. Human Gene Therapy, 1999, 10, 141-147.	2.7	26
52	Impairment of T-Cell Activation in Head and Neck Cancer In Situ and In Vitro. JAMA Otolaryngology, 1999, 125, 82.	1.2	31
53	Activation of the Epstein-Barr Virus Transcription Factor BZLF1 by 12- O -Tetradecanoylphorbol-13-Acetate-Induced Phosphorylation. Journal of Virology, 1998, 72, 8105-8114.	3.4	59
54	Downregulation of TAP1 in B Lymphocytes by Cellular and Epstein-Barr Virusâ€“Encoded Interleukin-10. Blood, 1997, 90, 2390-2397.	1.4	167